DRUG-RESISTANT TUBERCULOSIS: RECENT APPROACH IN POLYMER BASED NANOMEDICINE
Keywords:Tuberculosis, Drug resistant, Nanotechnology, Nanocarriers, Polymer, Pulmonary
Tuberculosis (TB) had been a leading chronic bacterial infection since decades. Current therapeutic management of Mycobacterium tuberculosis (MTB) is inadequate due to the lengthy course of treatment, drug-related side effects and ill-planned therapy, and these factors can lead to therapeutic failure and the emergence of drug-resistant TB. The Multi-drug-resistant (MDR) TB needs a lengthy course of treatment with second-line antitubercular drugs (ATDs) having higher side effects and cost. The misuse of second-line ATDs may result in extremely drug-resistant (XDR) strain which is very difficult to treat and require high doses of drugs resulting in more toxicity and side effects. This review highlights the need for novel drug delivery for the treatment of drug-susceptible and resistant TB. The characteristics of the nanoparticulate system in ATDs delivery and its approach in the MDR and XDR TB are discussed. The lung is the site of infection in pulmonary TB and the targeted drug delivery to the site of infection helps in achieving increased efficacy with less dose further reducing the side effects and toxicity. The symbiotic association of nanotechnology and pulmonary drug delivery give rise to an efficient inhalable polymer based nanoparticulate system containing ATDs for the better management of drug-susceptible and resistant TB. Various ATDs loaded polymer based nanocarrier systems like Alginate, PLGA, Chitosan and Gelatin nanocarriers are discussed in detail. Thus, this review highlights the current research in pulmonary drug delivery of polymer based ATDs nanomedicine and their importance in control of drug-resistant TB.
Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. J Am Med Assoc 2005;293:2767-75.
Zumla A, Raviglione M, Hafner R, Von Reyn CF. Tuberculosis. N Engl J Med 2013;368:745-55.
Meena L, Rajni. Survival mechanisms of pathogenic mycobacterium tuberculosis H37Rv. FEBS J 2010;277:2416-27.
Sarkar S, Suresh MR. An overview of tuberculosis chemotherapy-a literature review. J Pharm Pharm Sci 2011;14:148-61.
Zhang Y, Yew W. Mechanisms of drug resistance in mycobacterium tuberculosis. Int J Tuberculosis Lung Disease 2009;13:1320-30.
Kumar G, Malhotra S, Shafiq N, Pandhi P, Khuller G, Sharma S. In vitro physicochemical characterization and short-term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug-resistant tuberculosis. J Microencapsul 2011;28:717-28.
O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000;17:955-61.
Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 2001;18:1315-9.
Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target al. veolar macrophages for the treatment of pulmonary tuberculosis. Pharm Res 2001;18:1405-10.
Vyas S, Kannan M, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004;269:37-49.
Tewes F, Brillault J, Couet W, Olivier J. Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J Controlled Release 2008;129:93-9.
Sung J, Padilla D, Garcia-Contreras L, Ver Berkmoes J, Durbin D, Peloquin C, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009;26:1847-55.
Pandey R. Antitubercular inhaled therapy: opportunities, progress, and challenges. J Antimicrob Chemother 2005;55:430-5.
Gupta P, Garg T, Tanmay M, Arora S. Polymeric drug delivery systems: role in P-gp efflux system inhibition. Crit Rev Ther Drug Carrier Syst 2015;32:247-75.
Armstrong JA, Hart PD. The response of cultured macrophages to mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 1971;134:713-40.
Aderem A, Underhill D. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999;17:593-623.
Pethe K, Swenson D, Alonso S, Anderson J, Wang C, Russell D. Isolation of mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation. Proc Natl Acad Sci USA 2004;101:13642-7.
Krishnan N, Robertson B, Thwaites G. The mechanisms and consequences of the extra-pulmonary dissemination of mycobacterium tuberculosis. Tuberculosis 2010;90:361-6.
Singh S, Mariappan T, Shankar R, Sarda N, Singh B. A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm 2001;228:5-17.
Panchagnula R, Agrawal S, Ashokraj Y, Varma M, Sateesh K, Bhardwaj V, et al. Fixed-dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol 2004;26:703.
Addington W. Patient compliance: the most serious remaining problem in control of tuberculosis in the United States. Chest 1979;76 Suppl 6:741-3.
Bhutani H, Mariappan TT, Singh S. The physical and chemical stability of anti-tuberculosis fixed-dose combination products under accelerated climatic conditions. Int J Tuberculosis Lung Disease 2004;8:1073-80.
Ribeiro D. Nanocarrier systems for the delivery of antitubercular drugs. Master Thesis, University of Porto, Porto; 2013.
PDO Davies. Drug-resistant tuberculosis. J R Soc Med 2001;94:261-3.
Yashodhara B, Huat CB, Naik LN, Umakanth S, Hande M, Pappachan JM. Multidrug and extensively drug-resistant tuberculosis from a general practice perspective. Infect Drug Resist 2010;3:115-22.
Sun Z, Zhang J, Song H, Zhang X, Li Y, Tian M, et al. Concomitant increases in spectrum and level of drug resistance in mycobacterium tuberculosis isolates. Int J Tuberculosis Lung Disease 2010;14:1436-41.
Caminero J, Sotgiu G, Zumla A, Migliori G. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-9.
Gelperina S, Kisich K, Iseman M, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005;172:1487-90.
Faustini A, Hall AJ, Perucci CA. Risk factors for Multi-drug resistant tuberculosis in Europe: a systematic review. Thorax 2006;61:158-63.
Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberculosis Lung Disease 2012;16:1005-14.
Dutt M, Khuller G. Therapeutic efficacy of Poly(DL-Lactide-Co-Glycolide)-encapsulated antitubercular drugs against mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 2001;45:363-6.
Sharma A, Pandey R, Sharma S, Khuller G. Chemotherapeutic efficacy of poly (dl-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents 2004;24:599-604.
Pandey R, Zahoor A, Sharma S, Khuller G. Nanoparticle-encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 2003;83:373-8.
Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009;9:19-30.
Lopes E, Pohlman AR, Bassani V, Guterres SS. Polymeric colloidal systems containing ethionamide: preparation and physicochemical characterization. Pharmazie 2000;55:527-30.
Ahmad Z, Pandey R, Sharma S, Khuller G. Novel chemotherapy for tuberculosis: the chemotherapeutic potential of econazole and moxifloxacin-loaded PLG nanoparticles. Int J Antimicrob Agents 2008;31:142-6.
Kisich KO, Gelperina S, Higgins MP, Wilson S, Shipulo E, Oganesyan E, et al. Encapsulation of moxifloxacin within poly (butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular mycobacterium tuberculosis. Int J Pharm 2007;345(1, Suppl 2):154-62.
Ahmad Z, Sharma S, Khuller G. In vitro and ex vivo antimycobacterial potential of azole drugs against mycobacterium tuberculosis H 37 Rv. FEMS Microbiol Lett 2005;251:19-22.
Ahmad Z, Sharma S, Khuller G. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett 2006;261:181-6.
Ahmad Z, Sharma S, Khuller G, Singh P, Faujdar J, Katoch V. Antimycobacterial activity of econazole against multidrug-resistant strains of mycobacterium tuberculosis. Int J Antimicrob Agents 2006;28:543-4.
Pandey R, Khuller GK. Nanoparticle-based oral drug delivery system for an injectable antibiotic-streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy 2007;53:437-41.
Irache JM, Merodio M, Arnedo A, Camapanero MA, Mirshahi M, Espuelas S. Albumin nanoparticles for the intravitreal delivery of anti cytomegaloviral drugs. Mini Rev Med Chem 2005;5:293-305.
Gill S, LÃ¶benberg R, Ku T, Azarmi S, Roa W, Prenner E. Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery a review. J Biomed Nanotechnol 2007;3:107-19.
Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: in vivo performances. J Controlled Release 2012;160:418-30.
Shegokar R, Al Shaal L, Mitri K. Present status of nanoparticle research for treatment of tuberculosis. J Pharm Pharm Sci 2011;14:100-16.
Singh J, Garg T, Rath G, Goyal AK. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis-a critical review. Drug Delivery 2015;11:1-23.
Misra A, Hickey A, Rossi C, Borchard G, Terada H, Makino K, et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011;91:71-81.
Sethi T, Agrawal A. Structure and function of the tuberculous lung: considerations for inhaled therapies. Tuberculosis 2011;91:67-70.
Muttil P, Wang C, Hickey A. Inhaled drug delivery for tuberculosis therapy. Pharm Res 2009;26:2401-16.
Amani A, Amini M, Ali H, York P. Alternatives to conventional suspensions for pulmonary drug delivery by nebulizers: a review. J Pharm Sci 2011;100:4563-70.
Hokey D, Misra A. Aerosol vaccines for tuberculosis: a fine line between protection and pathology. Tuberculosis 2011;91:82-5.
Willis L, Hayes D, Mansour H. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 2012;190:251-62.
Kaur G, Narang R, Rath G, Goyal A. Advances in pulmonary delivery of nanoparticles. Artif Cells Blood Substitutes Immobilization Biotechnol 2012;40:75-96.
Beck-Broichsitter M, Kleimann P, Gessler T, Seeger W, Kissel T, Schmehl T. Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the AeronebÂ® pro: formulation aspects and nanoparticle stability to nebulization. Int J Pharm 2012;422:398-408.
Zahoor A, Sharma S, Khuller G. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26:298-303.
Jain SK, Gupta Y, Ramalingam L, Jain A, Jain A, Khare P, et al. Lactose-conjugated PLGA nanoparticles for enhanced delivery of rifampicin to the lung for effective treatment of pulmonary tuberculosis. PDA J Pharm Sci Technol 2010;64:278-87.
Pandey R. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52:981-6.
Sharma A. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as Oral/Aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004;54:761-6.
Tomoda K, Ohkoshi T, Kawai Y, Nishiwaki M, Nakajima T, Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray dryer inlet upon the properties of particles. Colloids Surf B 2008;61:138-44.
Ohashi K, Kabasawa T, Ozeki T, Okada H. One-step preparation of rifampicin/Poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Controlled Release 2009;135:19-24.
Moghaddam P, Ramezani V, Esfandi E, Vatanara A, Nabi-Meibodi M, Darabi M, et al. Development of a nano-micro carrier system for sustained pulmonary delivery of clarithromycin. Powder Technol 2013;239:478-83.
Cheow W, Chang MW, Hadinoto K. Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of release antibiotic profile. Pharm Res 2010;27:1597-609.
Grenha A, Seijo B, RemuÃ±Ã¡n-LÃ³pez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 2005;25:427-37.
Sharma K, Somavarapu S, Colombani A, Govind N, Taylor K. Crosslinked chitosan nanoparticle formulations for delivery from pressurized metered dose inhalers. Eur J Pharm Biopharm 2012;81:74-81.
Pourshahab P, Gilani K, Moazeni E, Eslahi H, Fazeli M, Jamalifar H. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J Microencapsul 2011; 28:605-13.
Saraogi G, Sharma B, Joshi B, Gupta P, Gupta UD, Jain NK, et al. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target 2011;19:219-27.
Abdulla J, Tan Y, Darwis Y. Rehydrated lyophilized rifampicin-loaded mPEG-DSPE formulations for nebulization. AAPS PharmSciTech 2010;11:663-71.
Kurmi B, Kayat J, Gajbhiye V, Tekade R, Jain N. Micro-and nanocarrier-mediated lung targeting. Expert Opin Drug Delivery 2010;7:781-94.
Weers J, Bell J, Chan H, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Delivery 2010;23 Suppl 2:S5-23.